What I do at MMV:
My role is to apply pharmacokinetic (PK) and pharmacodynamic (PD) models to characterize the relationship between the concentration of antimalarial compounds and their efficacy and safety. The aim of these activities is to optimize antimalarial drug translation from preclinical to clinical studies.
Why I work at MMV:
It is very motivating and rewarding for me to apply my expertise to the development of antimalarial medicines that can contribute to the control and ultimately, to the eradication of such a burdening disease, especially in vulnerable populations such as pregnant women and children. I particularly enjoy MMV’s multicultural environment and the opportunity to closely interact with other MMV functions and partners in order to achieve our common goal.
More about me:
I am a hospital pharmacist by training and after completing my residency in Spain, I moved to Switzerland where I obtained my PhD in 2018 within the Division of Clinical Pharmacology and Toxicology at the University Hospital in Lausanne. During this time, I developed several pharmacokinetic and pharmacogenetic models for antiretroviral drugs in collaboration with the Swiss HIV Cohort Study. I also applied my disease modelling skills to studying obesity in HIV-infected individuals. After having completed my PhD and before joining MMV, I worked at Debiopharm International where I conducted PK analyses for oncological drugs in phase I and II of clinical development.
Ask me about:
Besides pharmacokinetics/pharmacodynamics, oncology and infectious diseases. I am also happy to chat about travelling, cooking, films and swing dance.